Thyroid Cancer Trial, Recruiting NCT06356272 Sponsor: Mayo Clinic Condition: Thyroid Cancer
Back to Thyroid Cancer

Thyroid Cancer Trial, Recruiting

NCT06356272
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older
  • You must be able to sign a written consent form
  • You must be willing to allow your tumor, tissue, blood, and/or saliva samples to be used for research testing
  • You must be able to complete questionnaires on your own or with help
  • Your primary language must be English, Spanish, or Arabic
  • (For Groups 1–3) You must be willing and able to return in person to the enrolling hospital for at least 2 follow-up visits after your initial pre-treatment visit, for a total of 3 visits
  • (For Groups 1–3) Specific lab tests must be performed on your biopsy tissue to check for certain markers related to HPV (confirm with trial site)
  • (For Group 4) You have a suspected or confirmed diagnosis of a head and neck cancer or tumor, including cancers of the salivary glands, thyroid, or other head and neck areas, or a multi-cancer early detection blood test that raised concern for cancer

Who may not be able to join:

  • You are currently taking part in another clinical trial that involves a treatment for your cancer
  • (For Groups 1–3) You have had another active cancer within the past 5 years — exceptions include certain skin cancers, non-spreading thyroid cancer, non-spreading prostate cancer, a specific type of cervical pre-cancer, or HPV-related throat cancer (confirm with trial site)
  • (For Groups 1–3) You have a history of any previous head or neck cancer, other than the one currently being treated
  • (For Groups 1–3) You are currently receiving treatment for a previous cancer
  • (For Group 4, certain sub-groups) You have had another active cancer within the past 5 years — exceptions include non-spreading prostate cancer, a specific type of cervical pre-cancer, and a certain type of non-spreading skin cancer (confirm with trial site)
  • (For Group 4, certain sub-groups) You have a history of a previous head or neck cancer other than your current tumor, or you are still receiving treatment for another cancer — note that some sub-groups within Group 4 do allow this, so please confirm with the trial site

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kathryn M. Van Abel, MD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
15 November 2019
Est. completion
30 November 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in biomarkers; Oncologic outcomes associated with biomarkers; Genetic alterations; Immunologic biomarkers for diagnosis; Immunologic biomarkers for prognosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov